Insmed reported strong financial results for Q3 2024, with total revenue increasing 18.2% to $93.4 million compared to $79.1 million in Q3 2023. The growth was driven by ARIKAYCE sales expansion across all regions, with US revenue up 12.9% to $66.9 million, Japan revenue up 30.9% to $21.0 million, and Europe revenue up 45.3% to $5.6 million.Research and development expenses increased to $150.8 million from $109.1 million in Q3 2023, primarily due to higher manufacturing costs and increased headcount. SG&A expenses rose to $118.9 million from $90.6 million, driven by higher personnel costs and commercial readiness activities for brensocatib. The company reported a net loss of $220.5 million compared to $158.9 million in Q3 2023.The company maintained a strong financial position with $461.5 million in cash and cash equivalents plus $1.0 billion in marketable securities as of September 30, 2024. Insmed remains on track to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results. The company also closed screening for the ENCORE study of ARIKAYCE, with topline data expected in Q1 2026.

Insmed reported strong financial results for Q3 2024, with total revenue increasing 18.2% to $93.4 million compared to $79.1 million in Q3 2023. The growth was driven by ARIKAYCE sales expansion across all regions, with US revenue up 12.9% to $66.9 million, Japan revenue up 30.9% to $21.0 million, and Europe revenue up 45.3% to $5.6 million.Research and development expenses increased to $150.8 million from $109.1 million in Q3 2023, primarily due to higher manufacturing costs and increased headcount. SG&A expenses rose to $118.9 million from $90.6 million, driven by higher personnel costs and commercial readiness activities for brensocatib. The company reported a net loss of $220.5 million compared to $158.9 million in Q3 2023.The company maintained a strong financial position with $461.5 million in cash and cash equivalents plus $1.0 billion in marketable securities as of September 30, 2024. Insmed remains on track to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results. The company also closed screening for the ENCORE study of ARIKAYCE, with topline data expected in Q1 2026.